Evonik is restructuring to focus on its strategic core growth areas. Evonik will evaluate strategic options, such as partnerships or divestment, for developing its keto and pharma amino acid production sites in Ham and Wuming. It is also planning to discontinue its production of keto acids in Hanau by the end of 2025, affecting around 260 colleagues. Evonik’s keto and pharma amino acid business generates an annual average revenue of around 100 million euros.   As part of Evonik’s life sciences...